Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARRO Tumor-agnostic registrational trial of FYARRO in mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations to be initiated by the end of 2021 LOS ANGELES, June 04, 2021 (GLOBE NEWSWIRE) -- ... Read More